Skip to content

Author

R. Blauenfeldt

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Cardiometabolic drugs after stroke: time to embrace SGLT2 inhibitors and incretin-based therapies?

Stroke is a multifactorial cardiovascular disease (CVD), which predominantly affects older adults. Consequently, cardiovascular risk factors and related comorbidities are highly prevalent among people presenting with acute stroke. These conditions, and the stroke event itself, may require specific pharmacological thera...

H. Ihle-Hansen, H. Ihle-Hansen, R. Blauenfeldt et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.